9-21971044-G-A

Variant summary

Our verdict is Benign. The variant received -7 ACMG points: 2P and 9B. PM1BP4_StrongBP6BS2

The NM_058195.4(CDKN2A):​c.358C>T​(p.Arg120Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000619 in 1,453,282 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R120S) has been classified as Uncertain significance.

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000062 ( 1 hom. )

Consequence

CDKN2A
NM_058195.4 missense

Scores

16

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:1

Conservation

PhyloP100: -0.674

Publications

11 publications found
Variant links:
Genes affected
CDKN2A (HGNC:1787): (cyclin dependent kinase inhibitor 2A) This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
CDKN2A Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • melanoma-pancreatic cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • familial atypical multiple mole melanoma syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • melanoma and neural system tumor syndrome
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -7 ACMG points.

PM1
In a hotspot region, there are 6 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 19 benign, 32 uncertain in NM_058195.4
BP4
Computational evidence support a benign effect (MetaRNN=0.055409282).
BP6
Variant 9-21971044-G-A is Benign according to our data. Variant chr9-21971044-G-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 823962.
BS2
High AC in GnomAdExome4 at 9 AD gene.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_058195.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CDKN2A
NM_058195.4
MANE Plus Clinical
c.358C>Tp.Arg120Cys
missense
Exon 2 of 3NP_478102.2
CDKN2A
NM_000077.5
MANE Select
c.315C>Tp.Asp105Asp
synonymous
Exon 2 of 3NP_000068.1
CDKN2A
NM_001195132.2
c.315C>Tp.Asp105Asp
synonymous
Exon 2 of 4NP_001182061.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CDKN2A
ENST00000579755.2
TSL:1 MANE Plus Clinical
c.358C>Tp.Arg120Cys
missense
Exon 2 of 3ENSP00000462950.1
CDKN2A
ENST00000304494.10
TSL:1 MANE Select
c.315C>Tp.Asp105Asp
synonymous
Exon 2 of 3ENSP00000307101.5
CDKN2A
ENST00000498124.1
TSL:1
c.315C>Tp.Asp105Asp
synonymous
Exon 2 of 4ENSP00000418915.1

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD2 exomes
AF:
0.00000851
AC:
2
AN:
234900
AF XY:
0.00000775
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000942
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000619
AC:
9
AN:
1453282
Hom.:
1
Cov.:
31
AF XY:
0.00000830
AC XY:
6
AN XY:
723252
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33428
American (AMR)
AF:
0.00
AC:
0
AN:
44626
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26048
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39678
South Asian (SAS)
AF:
0.0000581
AC:
5
AN:
86104
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
46702
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5204
European-Non Finnish (NFE)
AF:
0.00000360
AC:
4
AN:
1111308
Other (OTH)
AF:
0.00
AC:
0
AN:
60184
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.532
Heterozygous variant carriers
0
1
3
4
6
7
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
Cov.:
32
Alfa
AF:
0.000184
Hom.:
1
ExAC
AF:
0.0000167
AC:
2

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Familial melanoma Uncertain:1
Sep 16, 2021
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Hereditary cancer-predisposing syndrome Benign:1
Dec 16, 2019
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

In silico models in agreement (benign);Other strong data supporting benign classification

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.12
BayesDel_addAF
Benign
-0.091
T
BayesDel_noAF
Benign
-0.27
CADD
Benign
7.3
DANN
Benign
0.97
DEOGEN2
Benign
0.0041
T
Eigen
Benign
-1.1
Eigen_PC
Benign
-1.1
FATHMM_MKL
Benign
0.17
N
LIST_S2
Benign
0.64
T
M_CAP
Benign
0.042
D
MetaRNN
Benign
0.055
T
MetaSVM
Benign
-0.96
T
PhyloP100
-0.67
PROVEAN
Benign
3.6
N
REVEL
Benign
0.17
Sift
Benign
0.22
T
Sift4G
Benign
0.15
T
Vest4
0.13
MVP
0.50
ClinPred
0.038
T
GERP RS
-5.5
PromoterAI
-0.037
Neutral
Mutation Taster
=3/97
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs763269347; hg19: chr9-21971043; COSMIC: COSV58684238; COSMIC: COSV58684238; API